MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Hesperidin lessens rotenone induced Parkinson diseases angiogenesis in nigrostriatal neuronal death through the AMPK/FOXO3 Signaling pathway

    DS. Singh (Allahabad, India)

    Objective: This study is to investigate the neuroprotective effect of HSP  in a mouse model of Parkinson's disease (PD) caused by rotenone, with an emphasis…
  • 2024 International Congress

    Pre-treatment with Methanolic Extract Mucuna pruriens Seeds Attenuates Serotonin Gene Depletion, Motor Dysfunction and Anxiogenic Responses in a Rat Model of Parkinsonism

    A. Obajuluwa, B. Laoye, J. Okwuaka, T. Obajuluwa, J. Lech, A. Oremosu (Ado -Ekiti, Nigeria)

    Objective: Investigate neuroprotective and genoprotective effects of methanolic Mucuna pruriens (Mp) seed extract in a paraquat-induced Parkinsonism rat model. Background: Paraquat exposure has been linked…
  • 2024 International Congress

    Nocturnal Hypertension in Parkinson’s Disease. The Flip Side of a Tainted Coin

    D. Wilson, M. Hagens, S. Nagaratnam, V. Fung (Sydney, Australia)

    Objective: To describe prevalence and severity of nocturnal hypertension and dipping in a cohort of patients with Parkinson’s disease undergoing 24hr blood pressure (BP) monitoring.…
  • 2024 International Congress

    Carbidopa does not cause changes in QTc interval even at a supratherapeutic dose

    R. Kleiman, J. Mickelson, R. Sanwo, C. Edwards, S. Fisher, H. Visser (South Gate, USA)

    Objective: To assess the cardiac safety of a single supratherapeutic dose of carbidopa in healthy adults. Background: Carbidopa has been approved for use in combination…
  • 2024 International Congress

    Palliative Care in Advanced Parkinson’s Disease: Descriptive Analysis and Symptom Impact

    C. Armengol-García, J. Hartmann-Nava, D. Martínez-Ramírez (Monterrey, Mexico)

    Objective: These preliminary study aims to describe the primary clinical features of Parkinson's disease patients requiring palliative care, as assessed by the Edmonton Symptom Assessment…
  • 2024 International Congress

    A case of malignant Deep Brain Stimulation Withdrawal Syndrome treated with Opicapone

    D. Brogle, L. Zünd-Hofer, F. Brugger, G. Kägi (Sankt Gallen, Switzerland)

    Objective: We present a case of a patient with Parkinson's disease who developed "malignant Deep Brain Stimulation (DBS) Withdrawal Syndrome" following the removal of the…
  • 2024 International Congress

    Alpha-synuclein affects PRMT5-mediated cytoprotective pathway in neuronally differentiated SH-SY5Y cell

    T. Nakamura, N. Sugeno, T. Hasegawa, K. Ikeda, S. Yoshida, S. Ishiyama, K. Sato, A. Takeda, M. Aoki (Sendai, Japan)

    Objective: To explore the impact of α-synuclein (αS) on PRMT5. Background: Alpha-synuclein (αS) is recognized as the pivotal molecule in the pathomechanism of Parkinson's disease.…
  • 2024 International Congress

    Investigating the pathogenesis of GBA1-associated Parkinson’s disease using GBA1 isogenic iPSC lines

    Y. Chen, C. Chen, C. Ma, J. Lichtenberg, E. Hertz, T. Jong, R. Sam, Y. Li, S. Vrisjen, P. Vangheluwe, C. Blauwendraat, E. Sidransky (Bethesda, USA)

    Objective: We aim to explore the pathogenesis of GBA1-associated synucleinopathies and discern the gain- vs. loss-of-function hypotheses by genetically engineering GBA1 in an iPSC line derived…
  • 2024 International Congress

    Sphingomyelinase Activity in Patients with Sporadic Parkinson’s Disease

    A. Rekik, A. Mili, S. Naija, E. Jarrar, K. Jemai, A. Hassine, S. Ben Amor, J. Ben Abdallah (Sousse, Tunisia)

    Objective: To measure the sphingomyelinase (ASMase) activity in sporadic PD patients and matched healthy controls and identify any clinical or biological correlation with disease’s severity.To…
  • 2024 International Congress

    PARKIN gene replacement by AAV-mediated gene delivery as a therapeutic modality for PARKIN-deficient early-onset familial Parkinson’s disease

    N. Gattone, AJ. Gilsrud, S. Basu, T. Demarest, B. Wicks, E. Kostuk, D. Narendra, MG. Biferi, E. Ramsburg (Philadelphia, USA)

    Objective: Evaluate PARKIN gene replacement by adeno-associated virus (AAV) vector as a therapeutic modality in relevant disease models of early-onset Parkinson’s Disease (EOPD). Background: Biallelic…
  • « Previous Page
  • 1
  • …
  • 111
  • 112
  • 113
  • 114
  • 115
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley